secwatch.observer — SEC 8-K summary
======================================

Issuer:     OS Therapies Inc (OSTX)
CIK:        0001795091
Form:       8-K
Filed at:   2025-08-19T23:59:59+00:00
Accession:  0001213900-25-078152
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OS Therapies Q2 net loss $4.5M; FDA confirms RMAT, issues BLA number for OST-HER2, Phase 2b data positive
--------------------------------------------------------------------------------

- FDA confirmed OST-HER2 meets biological criteria for RMAT; issued BLA number for Accelerated Approval submission.
- Phase 2b trial: 12-month EFS 35% vs 20% (p=0.0197), interim 2-year OS 66.6% vs 40% (p=0.0046).
- Q2 2025 net loss $4.537M vs $1.557M YoY; EPS loss $0.19 on 25.1M shares vs $0.26 on 5.99M shares.
- End of Phase 2 FDA meeting scheduled Aug 27, 2025; projected rolling BLA submission late Q3 2025.
- $4.2M capital raise closed July 11; entered ATM offering up to $18M; commercial partner Eversana for possible 1H 2026 launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025078152/0001213900-25-078152-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1795091/000121390025078152/ea0253711-8k_ostherap.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-078152

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer